JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on October 15, 2003; DOI: 10.1124/jpet.103.057422


0022-3565/03/3073-932-938$20.00
JPET 307:932-938, 2003
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.057422v1
jpet.103.057422v2
307/3/932    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ju, H.
Right arrow Articles by Willette, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ju, H.
Right arrow Articles by Willette, R. N.

CARDIOVASCULAR

p38 MAPK Inhibitors Ameliorate Target Organ Damage in Hypertension: Part 1. p38 MAPK-Dependent Endothelial Dysfunction and Hypertension

Haisong Ju1, David J. Behm1, Sandyha Nerurkar, Marianne E. Eybye, Robin E. Haimbach, Alan R. Olzinski, Stephen A. Douglas, and Robert N. Willette

Departments of Investigative and Cardiac Biology and Vascular Biology, Cardiovascular and Urogenital Center of Excellence in Drug Discovery, GlaxoSmithKline, King of Prussia, Pennsylvania

Numerous mediators, believed to play a role in endothelial dysfunction (e.g., neurohormones, cytokines, hypoxia, and stretch), have been shown to activate p38 mitogen-activated protein kinase (MAPK) in a variety of cell types. The purpose of the present study was to examine the regulation of p38 MAPK in endothelium and its role in endothelial dysfunction and salt sensitivity. In cultured human umbilical vein endothelial cells (HUVECs), tumor necrosis factor-{alpha} and lipopolysaccharide increased phosphorylation of p38 MAPK (P-p38 MAPK) and increased ICAM-1 expression. Preincubation with highly selective p38 MAPK inhibitors, 1-(1,3-dihydroxyprop-2-yl)-4-(4-fluorophenyl)-5-[2-phenoxypyrimidin-4-yl] imidazole (SB-239063AN) or SB-239063, dose dependently reduced intercellular adhesion molecule-1 expression in HUVECs. In spontaneously hypertensive-stroke prone rats (SHR-SP), P-p38 MAPK was localized by immunohistochemistry to the aortic endothelium and adventitia but was undetectable in aortae from normotensive rats. Introduction of a salt/fat diet (SFD) to the SHR-SP strain induced endothelial dysfunction (ex vivo vascular reactivity analysis), albuminuria, and an increase in blood pressure within 4 weeks. Chronic dietary dosing (approx. 100 mg/kg/day) with SB-239063AN inhibited the SFD diet-induced hypertension. In addition, delayed treatment also significantly improved survival and restored nitric oxide-mediated endothelium-dependent relaxation in SFD-SHR-SPs with established endothelial dysfunction. These results suggest an important role for p38 MAPK in endothelial inflammation and dysfunction as well as providing the first evidence for p38 MAPK-dependent hypertension.


Received July 22, 2003; accepted September 16, 2003.

Address correspondence to: Dr. Robert N. Willette, Department of Investigative and Cardiac Biology, UW2510, GlaxoSmithKline, 709 Swedeland Rd., P.O. Box 1539, King of Prussia, PA 19406. E-mail: Robert_n_willette{at}gsk.com




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. P. Weerackody, D. J. Welsh, R. M. Wadsworth, and A. J. Peacock
Inhibition of p38 MAPK reverses hypoxia-induced pulmonary artery endothelial dysfunction
Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1312 - H1320.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
Y. Li, X. Zhang, B. Zhu, and Z. Xue
Desflurane Preconditioning Inhibits Endothelial Nuclear Factor-{kappa}-B Activation by Targeting the Proximal End of Tumor Necrosis Factor-{alpha} Signaling
Anesth. Analg., May 1, 2008; 106(5): 1473 - 1479.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. B. Morris, A. R. Olzinski, R. E. Bernard, K. Aravindhan, R. C. Mirabile, R. Boyce, R. N. Willette, and B. M. Jucker
p38 MAPK Inhibition Reduces Aortic Ultrasmall Superparamagnetic Iron Oxide Uptake in a Mouse Model of Atherosclerosis: MRI Assessment
Arterioscler. Thromb. Vasc. Biol., February 1, 2008; 28(2): 265 - 271.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
G. Li, E. J. Barrett, M. O. Barrett, W. Cao, and Z. Liu
Tumor Necrosis Factor-{alpha} Induces Insulin Resistance in Endothelial Cells via a p38 Mitogen-Activated Protein Kinase-Dependent Pathway
Endocrinology, July 1, 2007; 148(7): 3356 - 3363.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H.-Y. Liu, Q. F. Collins, Y. Xiong, F. Moukdar, E. G. Lupo Jr., Z. Liu, and W. Cao
Prolonged Treatment of Primary Hepatocytes with Oleate Induces Insulin Resistance through p38 Mitogen-activated Protein Kinase
J. Biol. Chem., May 11, 2007; 282(19): 14205 - 14212.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
W. Chai and Z. Liu
p38 Mitogen-Activated Protein Kinase Mediates Palmitate-Induced Apoptosis But Not Inhibitor of Nuclear Factor-{kappa}B Degradation in Human Coronary Artery Endothelial Cells
Endocrinology, April 1, 2007; 148(4): 1622 - 1628.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. Doe, R. Bentley, D. J. Behm, R. Lafferty, R. Stavenger, D. Jung, M. Bamford, T. Panchal, E. Grygielko, L. L. Wright, et al.
Novel Rho Kinase Inhibitors with Anti-inflammatory and Vasodilatory Activities
J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 89 - 98.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Nozawa, K.-i. Sugimoto, M. Ohmori, H. Ando, and A. Fujimura
Dosing Time-Dependent Effect of Temocapril on the Mortality of Stroke-Prone Spontaneously Hypertensive Rats
J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 176 - 181.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
W. Cao, Q. F. Collins, T. C. Becker, J. Robidoux, E. G. Lupo Jr., Y. Xiong, K. W. Daniel, L. Floering, and S. Collins
p38 Mitogen-activated Protein Kinase Plays a Stimulatory Role in Hepatic Gluconeogenesis
J. Biol. Chem., December 30, 2005; 280(52): 42731 - 42737.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
H. Li and E. P. Nord
CD40/CD154 ligation induces mononuclear cell adhesion to human renal proximal tubule cells via increased ICAM-1 expression
Am J Physiol Renal Physiol, July 1, 2005; 289(1): F145 - F153.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. E. McMullen, P. W. Bryant, C. C. Glembotski, P. A. Vincent, and K. M. Pumiglia
Activation of p38 Has Opposing Effects on the Proliferation and Migration of Endothelial Cells
J. Biol. Chem., June 3, 2005; 280(22): 20995 - 21003.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. R. Olzinski, T. A. McCafferty, S. Q. Zhao, D. J. Behm, M. E. Eybye, K. Maniscalco, R. Bentley, K. S. Frazier, C. M. Milliner, R. C. Mirabile, et al.
Hypertensive target organ damage is attenuated by a p38 MAPK inhibitor: role of systemic blood pressure and endothelial protection
Cardiovasc Res, April 1, 2005; 66(1): 170 - 178.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. Widder, T. Behr, D. Fraccarollo, K. Hu, P. Galuppo, P. Tas, C. E Angermann, G. Ertl, and J. Bauersachs
Vascular endothelial dysfunction and superoxide anion production in heart failure are p38 MAP kinase-dependent
Cardiovasc Res, July 1, 2004; 63(1): 161 - 167.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.